Daiichi Sankyo returns Yescarta marketing authorization in Japan to Gilead

8 December 2022

Japanese drug major Daiichi Sankyo’s (TYO: 4568) shares edged up nearly 2% to 4,426 yen today, after it announced it was giving up Japanese marketing rights to Yescarta (axicabtagene ciloleucel).

Yescarta is a CAR T-cell therapy for adult patients with large B-cell lymphoma developed by Kite Pharma and licensed to Daichi in 2017. Kite was acquired by Gilead Sciences (Nasdaq: GILD) later in 2017 after the Daiichi Sankyo partnership agreement.

Daiichi Sankyo and Kite have now agreed that the marketing authorization for Yescarta will be transferred to Gilead in 2023. A Kite cell therapy business unit at Gilead Sciences KK will manage the sales and promotion activities of the product in Japan after the Marketing Authorization transfer. Yescarta was approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) in January last year. Global sales of Yescarta increased 81% to $317 million in the third quarter of this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK